Gene · 84335
Papers2,881
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
21 to 40 of 2,881
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The effects of LINC00324 on cell proliferation, migration, and invasion via autophagy in melanoma. | Sci Rep | 2026 | 41526496 | PubTator, text mining | PubMed |
| Leveraging Menstrual Effluent to Investigate Vitamin D and Human Decidualization: A Potential Link with Fertility. | J Clin Endocrinol Metab | 2026 | 41492807 | PubTator, text mining | PubMed |
| PRAS40 promotes colorectal cancer stemness by enhancing glycolysis through triggering PGK1 acetylation. | Oncogenesis | 2025 | 41455783 | PubTator, text mining | PubMed |
| Proteome-Wide Monitoring of Drug Action in Living Cells Using a Novel Label-Free Solvent-Based Shift Assay. | Mol Cell Proteomics | 2025 | 41202878 | PubTator, text mining | PubMed |
| Comprehensive proteomic and pathological profiling identifies PRAS40 as a novel biomarker and mediator of primary immune checkpoint blockade resistance in non-small cell lung cancer. | Cancer Immunol Immunother | 2025 | 41071193 | PubTator, text mining | PubMed |
| The Omega-3 Fatty Acids Eicosapentaenoic Acid and Docosahexaenoic Acid Enhance the Effects of Temozolomide Chemotherapy in Glioblastoma Cells. | Int J Mol Sci | 2025 | 41009329 | PubTator, text mining | PubMed |
| Loss of the tumor suppressor PTEN activates cell-intrinsic interferon signaling to drive immune resistance. | bioRxiv | 2025 | 41000885 | PubTator, text mining | PubMed |
| Are metformin-based combination approaches beneficial for non-small cell lung cancer: evidence from experimental and clinical studies. | Mil Med Res | 2025 | 40983975 | PubTator, text mining | PubMed |
| Amino acid-dependent TSC2 dephosphorylation by lysosome-PP2A regulates mTORC1 signaling transduction. | Life Sci Alliance | 2025 | 40897470 | PubTator, text mining | PubMed |
| Integrating single-cell regulatory atlas and multi-omics data for differential treatment response and multimodal predictive modeling in CDK 4/6 inhibitor-treated breast cancer. | Front Oncol | 2025 | 40746611 | PubTator, text mining | PubMed |
| AKT inhibitors in gynecologic oncology: past, present and future. | Front Oncol | 2025 | 40746599 | PubTator, text mining | PubMed |
| DNFE: Directed network flow entropy for detecting tipping points during biological processes. | PLoS Comput Biol | 2025 | 40729372 | PubTator, text mining | PubMed |
| The role of autophagy in ischemic brain injury. | Autophagy Rep | 2025 | 40395988 | PubTator, text mining | PubMed |
| Development of Acquired Resistance in Alpelisib-treated Gastric Cancer Cells With PIK3CA Mutations and Overcoming Strategies. | Anticancer Res | 2025 | 40295072 | PubTator, text mining | PubMed |
| Effects of empagliflozin and its combination with docetaxel on LNCaP and DU- 145 prostate cancer cell lines: cytotoxicity and molecular pathway analysis. | Naunyn Schmiedebergs Arch Pharmacol | 2025 | 40227306 | PubTator, text mining | PubMed |
| Huntingtin-Interacting Protein 1-Related (HIP1R) Regulates Rheumatoid Arthritis Synovial Fibroblast Invasiveness. | Cells | 2025 | 40214437 | PubTator, text mining | PubMed |
| Fluoxetine Suppresses Osteosarcoma Progression In Vivo by Inducing Apoptosis and Inhibiting the AKT/mTOR/NF-κB Signaling Pathway. | Anticancer Res | 2025 | 40155004 | PubTator, text mining | PubMed |
| PTMNavigator: interactive visualization of differentially regulated post-translational modifications in cellular signaling pathways. | Nat Commun | 2025 | 39779715 | PubTator, text mining | PubMed |
| High-density lipoprotein protects normotensive and hypertensive rats against ischemia-reperfusion injury through differential regulation of mTORC1 and mTORC2 signaling. | Front Pharmacol | 2024 | 39611167 | PubTator, text mining | PubMed |
| Phospholipase Cδ-4 (PLCδ4) Acts as a Nuclear Player to Influence Cyclin B Expression in the Embryonal Rhabdomyosarcoma Cell Lines RD and A204. | Biomolecules | 2024 | 39334946 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/84335/papers?page=2